key: cord-0823044-5nz0bs4v
authors: Masini, Francesco; Gjeloshi, Klodian; Ferrara, Roberta; Pinotti, Emanuele; Cuomo, Giovanna
title: Rheumatic disease management in the Campania region of Italy during the COVID-19 pandemic
date: 2020-07-14
journal: Rheumatol Int
DOI: 10.1007/s00296-020-04648-8
sha: ceb99303a5a06813d5f89d9adbb57ca2c9c84d6c
doc_id: 823044
cord_uid: 5nz0bs4v

nan

may be more susceptible to the infection, mainly in combination with biologic drugs [3] . Unlike other viruses (e.g., influenza), coronaviruses have not been shown to evolve to the more severe stages of the disease in immunosuppressed patients [4] . Usually, discontinuing therapeutic treatment is not recommended, since clinical flares of rheumatic disease develop with subsequent use of other immunosuppressants such as corticosteroids, equally unsafe in the case of COVID-19 occurrence [3] . Indeed, the risk of infection in rheumatic patients (i.e., rheumatoid arthritis) is also related to disease activity and a flare due to therapy interruption would confer an increased risk of infection. The European League Against Rheumatism (EULAR) and the Italian Society of Rheumatology (SIR) clinical guidance during COVID-19 pandemic recommended management of patients on long-term corticosteroid therapy by gradually tapering doses, and warning against abrupt cessation of corticosteroid therapy, even during active infection. Discontinuation of disease-modifying antirheumatic drugs, biologics, small molecules, and other immunosuppressive agents has been suggested just in case of overt infection [5] . SIR has also promoted a dedicated platform, "CONTROL-19", for the remote monitoring of COVID-19 impact on rheumatic diseases [6] . In our internal medicine outpatient, we have closely monitored patients with severe active disease either via phone-calls or e-mail, rescheduling the great majority of appointments and implementing restrictive measures at a social level [7] . We have selected patients that could not postpone their infusion, providing them with specific recommendations. In cases of extremely urgent need to initiate treatment, subcutaneous infusions were preferred over intravenous biologics, as they can be taken at home. An objective phone interview has been carried out before admission to assess for acute respiratory symptoms, and/or fever, and exclude contact with positive COVID-19 patients during the past 14 days. Infusions have been provided in a dedicated room, with access reserved only to one doctor and a nurse, equipped with individual protection devices to detect rapid IgM-IgG SARS-CoV-2 antibody test. No accompanying person was allowed. A three-layer surgical mask, hand sanitizer and a disposable glove box was available at the entrance of the dedicated area. In the case of positive history, COVID-19 like symptoms or history of contact, both patient and attendant were isolated and treated as COVID-19 positive unless otherwise proven. Our protocol enforces to inform hospital administration authority [8] [9] [10] .

Although more evidence is required to demonstrate the real impact of this strategy, telemedicine has demonstrated as a valid alternative to improve the quality of rheumatic patients' care during COVID-19 pandemic, thus reducing hospitalizations only to urgent admissions. We surprisingly report only one patient contacting us due to COVID-19 infection, and a limited number of urgent admissions during the lockdown period. Since the clinical examination and psychological implications derived from this period remain of fundamental importance, it would be useful to invest in new personalized patients' care strategies. Further studies would be worthied to establish appropriate and evidencebased strategies to be prepared to face with a likely second cycle of pandemic, expected for next autumn.

Conflicts of interest "The authors have no conflict of interest to disclose."

Evolvingepidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study

Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients China

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

What does the COVID-19 pandemic mean for rheumatology patients?

Prediction of infection risk in rheumatoidarthritis patients treated with biologics: are we any closer to riskstratification?

EULAR (2020) EULAR guidance for patients during Covid-19 outbreak (2020)

SIR (2020) COVID-19 monitoring in patients with rheumatic and musculoskeletal diseases

Rheumatology and COVID-19

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Global rheumatology in the time of COVID-19